Argidene gel data

TLIO (San Diego) reported accelerated healing and reduced need for skin grafts in 57 patients, average age 2 1/2 years, compared to standard therapy with silver sulfadiazine cream. The primary endpoint of the pivotal device trial was number of days to achieve 90 percent epithelialization, or closure, of the wound.

Healing of sites treated with the product occurred 2.1 days earlier (9.3 days compared to 11.5 days, p = 0.003) compared to control sites on the same patient. Nine patients required skin grafts, with seven requiring grafting of their control sites while the gel-treated site healed without the need for grafting. Two patients required grafting at both the treated and control sites. ...